The FDA granted fast track designations for multiple oncology programs in July 2026, signaling continued regulatory focus on faster development pathways for difficult-to-treat cancers. SOTIO Biotech received fast track for SOT109, a CDH17-targeting ADC, in advanced metastatic colorectal cancer after standard options. Oncology fast track also covered Oncolytics Biotech’s pelareorep in combination with atezolizumab for squamous cell anal canal cancer, with designation based on GOBLET study efficacy signals. Pfizer’s talazoparib (Talzenna) received priority review for a supplemental application in HRR gene–altered metastatic castration-sensitive prostate cancer, driven by TALAPRO-3 results showing a risk reduction versus placebo. Taken together, the actions extend the FDA’s emphasis on conditional review for targeted mechanisms, biomarker-defined populations, and combination regimens where unmet need remains high.